Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of SHR-A1811 in HER2-expressing recurrent or metastatic cervical cancer after platinum and checkpoint inhibitor failure
CTR20252583Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in Cervical Cancer (CC), sponsored by Hengrui Therapeutics. Started Oct 2025; status: active.
02
Drugs
trastuzumab rezetecan
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20252583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252583.